Scarica l'app Stockscreener
32.59
19.71%
-8.00
Dopo l'orario di chiusura:
31.51
-1.08
-3.31%
Precedente Chiudi:
$40.59
Aprire:
$40.57
Volume 24 ore:
558.69K
Relative Volume:
1.35
Capitalizzazione di mercato:
$1.75B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-17.21%
1M Prestazione:
-6.89%
6M Prestazione:
+215.49%
1 anno Prestazione:
+265.36%
Intervallo 1D:
$31.51
$41.10
Intervallo di 1 settimana:
$31.51
$41.10
Portata 52W:
$5.83
$41.50
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Nome
Zenas Biopharma Inc
Settore
Industria
Telefono
857-271-2954
Indirizzo
852 WINTER STREET, SUITE 250, WALTHAM
Confronta ZBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
32.59 | 2.18B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-20 | Iniziato | Wedbush | Outperform |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Citigroup | Buy |
| 2024-10-08 | Iniziato | Guggenheim | Buy |
| 2024-10-08 | Iniziato | Jefferies | Buy |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Zenas Biopharma Inc Borsa (ZBIO) Ultime notizie
Zenas BioPharma Approves 2026 Inducement Plan - TipRanks
Zenas BioPharma (NASDAQ:ZBIO) Shares Down 9.9%Should You Sell? - MarketBeat
ZBIO STOCKHOLDERS: Contact Robbins LLP for Information About How - GuruFocus
InnoCare Pharma achieves primary endpoint in Phase 2b study of orelabrutinib - TipRanks
Innocare Pharma announces achievement of primary endpoint in phase 2b study of orelabrutinib - marketscreener.com
Zenas BioPharma’s Partner, InnoCare Pharma, Announces - GlobeNewswire
Zenas Prepares For INDIGO Phase 3 Readout—Reinstating Buy Rating (ZBIO) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
IgG4-related Disease Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Zenas BioPharma, Horizon Therapeutics, Amgen, Sanofi, UMC Utrecht - The Globe and Mail
Is Zenas BioPharma’s (ZBIO) Royalty Deal Quietly Rewriting Its Late-Stage Risk Profile? - Sahm
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Federated Hermes Inc. Boosts Stake in Zenas BioPharma, Inc. $ZBIO - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Hits New 52-Week HighHere's Why - MarketBeat
Zenas Biopharma stock hits all-time high at 41.37 USD By Investing.com - Investing.com Canada
Zenas Biopharma stock hits all-time high at 41.37 USD - Investing.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Investors to Connect - ACCESS Newswire
Is Zenas BioPharma Stock Built to Withstand More Downside? - Trefis
Taking Stock of Zenas BioPharma (ZBIO) Valuation After Royalty Pharma Financing Boost - Sahm
2025-12-04 | Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Stockholders to Inquire about Securities Investigation | NDAQ:ZBIO | Press Release - Stockhouse
Meridian Small Cap Growth Fund Trimmed Zenas BioPharma (ZBIO) Following Share Price Appreciation - Insider Monkey
Is Zenas BioPharma Inc. stock trading near support levelsQuarterly Trade Report & Low Risk Entry Point Guides - Newser
Can Zenas BioPharma Stock Hold Up When Markets Turn? - Trefis
Did You Lose Money on Zenas BioPharma, Inc. (ZBIO)? Levi & Korsinsky Urges Investors to Act Before June 16, 2025 - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Securities Lawsuit Alert: Zenas BioPharma, Inc. (ZBIO)Contact Levi & Korsinsky Before June 16, 2025 - The National Law Review
ZBIO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
ZBIO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
EV Market: How interest rate cuts could boost Zenas BioPharma Inc. stockWeekly Loss Report & Reliable Breakout Stock Forecasts - BỘ NỘI VỤ
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 3.5%Here's What Happened - MarketBeat
Update Report: Can Zenas BioPharma Inc. stock reach $100 price targetJuly 2025 Levels & Weekly Breakout Opportunity Watchlist - moha.gov.vn
Zenas BioPharma Reports Q3 2025 Financial Results - MSN
How interest rate cuts could boost Zenas BioPharma Inc. stockWeekly Trade Summary & Real-Time Market Sentiment Reports - BỘ NỘI VỤ
Evercore ISI Initiates Coverage on Zenas BioPharma (NASDAQ:ZBIO) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Stockholders to Reach Out - ACCESS Newswire
Zenas BioPharma (NASDAQ:ZBIO) Now Covered by Evercore ISI - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Reaches New 52-Week HighShould You Buy? - MarketBeat
Can Zenas BioPharma's (ZBIO) Improving Loss Per Share Shift Investor Confidence in Its Long-Term Story? - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Stockholders to Connect - ACCESS Newswire
Zenas Biopharma stock hits all-time high at 38.92 USD By Investing.com - Investing.com Australia
Zenas Biopharma stock hits all-time high at 38.92 USD - Investing.com
IgG4-related disease Market Size was USD 170 million in 2024, - openPR.com
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Zenas BioPharma : Corporate Presentation - MarketScreener
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO) - PR Newswire
Will Zenas BioPharma Inc. benefit from macro trendsEarnings Beat & Verified High Yield Trade Plans - newser.com
Is Zenas BioPharma Inc. stock a dividend growth opportunityDollar Strength & High Conviction Investment Ideas - newser.com
Will Zenas BioPharma Inc. stock keep outperforming rivalsMarket Sentiment Summary & Verified Technical Trade Signals - newser.com
Will Zenas BioPharma Inc. stock remain a Wall Street favoriteEarnings Performance Report & Risk Controlled Swing Alerts - newser.com
Would You Accumulate or Wait on Jagran Prakashan Limited (JAGRAN)Earnings Season Recap & These Picks Are Just One Breakout Away - earlytimes.in
Zenas Biopharma Inc Azioni (ZBIO) Dati Finanziari
Non sono disponibili dati finanziari per Zenas Biopharma Inc (ZBIO). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):